Sepsis Diagnosis Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 0.74 Billion |
| Market Size (2029) | USD 1.02 Billion |
| CAGR (2024 - 2029) | 6.58 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Sepsis Diagnosis Market Analysis
The Global Sepsis Diagnostics Market size is estimated at USD 0.74 billion in 2024, and is expected to reach USD 1.02 billion by 2029, growing at a CAGR of 6.58% during the forecast period (2024-2029).
Increasing incidences of sepsis in COVID-19 patients is anticipated to have a positive impact on the market studied. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', the analysis of the 2020 acute care hospitals standardized infection ratios found significant increases in central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated events, and methicillin-resistant Staphylococcus aureus bacteremia compared to 2019. The largest increases occurred during quarter 4 of 2020. Furthermore, according to a study published by PLOS in August 2021, 'Immunometabolic signatures predict the risk of progression to sepsis in COVID-19,' COVID-19 patients are at the highest risk of developing sepsis. Hence, this is expected to create new opportunities for novel diagnosis in the market studied.
The major factors for the growth of the sepsis diagnostics market include the increasing burden of sepsis, the growing burden of hospital-acquired infections, the increasing number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities. Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', about 24%, 35%, and 15% increase in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia between 2019 and 2020 in the United States. The rising bloodstream infections will lead to increased adoption of sepsis diagnostic products. Additionally, in June 2021, the collaboration led by the University of Liverpool has received more than GBP 3 million in funding for a new intervention that will actively prevent, treat and evaluate maternal sepsis.
Thus, the rise in the prevalence of sepsis and increase in funding for research activities for sepsis diagnosis are expected to drive the overall growth of the sepsis diagnosis market over the forecast period.
Sepsis Diagnosis Market Trends
This section covers the major market trends shaping the Sepsis Diagnostics Market according to our research experts:
The Molecular Diagnostics Segment Has a Significant Share in the Market
Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Moreover, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis diagnostics.
Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods. The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method. However, the cost of molecular diagnostics has remained very high, as compared to conventional procedures, which restricts its market growth. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For instance, in October 2020, Immunexpress launched a rapid SeptiCyte, a one-hour molecular diagnostic test for sepsis in Europe on Biocartis' Idylla platform. This is one of the first rapid, fully-integrated, and immune response-based tests to aid clinicians with a sepsis diagnosis.
Furthermore, researchers are attempting to develop a molecular diagnostic that can detect the COVID-19 and sepsis, as well as discriminate between the two. In November 2020, the Hellenic Institute for the Study of Sepsis and, in part by Sanmina Corporation, funded a study and developed a novel optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of this segment.
North America is Expected to Hold a Large Share of the Market
North America is found to hold a major share of the sepsis diagnostics market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the Centers for Disease Control and Prevention, in August 2021, approximately 1.7 million adults in America develop sepsis, and nearly 270,000 Americans die due to sepsis. It was also found that 1 in 3 patients who die in a hospital has sepsis. Thus, the high incidence rate of the disease in the country will boost its diagnosis, thus, boosting the market.
Moreover, rising investments in the fields of research and development for the diagnosis of sepsis will also boost the market. For instance, in April 2020, Cytovale Inc. expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA) for diagnosing sepsis in patients with potential respiratory infections, including COVID-19. The research is estimated to stand at the cost of USD 5.9 million, with approximately USD 3.83 contributed by the Biomedical Advanced Research and Development Authority (BARDA), thus, driving the market.
Therefore, the rising prevalence of sepsis and increasing investments in the research and development of sepsis diagnosis may augment the growth of the market in the United States.
Sepsis Diagnosis Industry Overview
The sepsis diagnostics market is moderately consolidated owing to the presence of a few key players. The market is expected to drive due to the products launched by the key players in the market and the rise in research initiatives on sepsis diagnostics by the key players. Some of the market players are Abbott, Becton, Dickinson, and Company, bioMérieux SA, Bruker Corporation, F. Hoffmann-LA Roche Ltd, and Immunexpress Inc., among others.
Sepsis Diagnosis Market Leaders
-
Abbott
-
Diasorin
-
Becton, Dickinson, and Company
-
bioMérieux SA
-
F. Hoffmann-LA Roche Ltd
*Disclaimer: Major Players sorted in no particular order
Sepsis Diagnosis Market News
- In December 2021, Immunoexpress received the United States Food and Drug Administration (FDA) approval for SeptiCyte RAPID.
- In October 2021, Prenosis Inc., a precision diagnostics firm that uses artificial intelligence to enhance clinical diagnosis, expanded its existing agreement with Roche Diagnostics to improve and speed the clinical detection of sepsis.
Sepsis Diagnosis Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Sepsis
4.2.2 Growing Incidence of Hospital-acquired Infections
4.2.3 Rise in the Number of Sepsis Procedures and Increase in Funding for Sepsis-related Research Activities
4.3 Market Restraints
4.3.1 High Cost of Automated Diagnostic Instruments
4.3.2 Lack of Well-established Reimbursement Policies for Sepsis
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Technology
5.1.1 Molecular Diagnostics
5.1.2 Microbiology
5.1.3 Immunoassay
5.1.4 Other Technologies
5.2 By Product
5.2.1 Instruments
5.2.2 Assays and Reagents
5.2.3 Other Products
5.3 By Diagnostic Method
5.3.1 Conventional Diagnostics
5.3.2 Automated Diagnostics
5.4 By Pathogen
5.4.1 Bacterial Sepsis
5.4.2 Fungal Sepsis
5.4.3 Other Pathogens
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories Inc.
6.1.2 Axis-Shield Diagnostics Ltd
6.1.3 Becton, Dickinson, and Company
6.1.4 BioMerieux SA
6.1.5 Bruker Corporation
6.1.6 Cube Dx GmbH
6.1.7 Danaher Corporation
6.1.8 EKF Diagnostics
6.1.9 F. Hoffmann-LA Roche Ltd
6.1.10 Immunexpress Inc.
6.1.11 Diasorin
6.1.12 Response Biomedical Corp.
6.1.13 Sysmex Corporation
6.1.14 T2 Biosystems Inc.
6.1.15 Thermo Fisher Scientific
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Sepsis Diagnosis Industry Segmentation
As per the scope of this report, sepsis diagnostics is the study of diagnosis of sepsis, which is a serious and life-threatening clinical condition that generally results from primary bacterial infection or, less frequently, from a fungal and/or viral infection. The sepsis diagnostics market is segmented by technology (molecular diagnostics, microbiology, immunoassay, and other technologies), product (instruments, assays and reagents, other products), diagnostic method (conventional diagnostics, automated diagnostics), pathogen (bacterial sepsis, fungal sepsis, other pathogens), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Technology | |
| Molecular Diagnostics | |
| Microbiology | |
| Immunoassay | |
| Other Technologies |
| By Product | |
| Instruments | |
| Assays and Reagents | |
| Other Products |
| By Diagnostic Method | |
| Conventional Diagnostics | |
| Automated Diagnostics |
| By Pathogen | |
| Bacterial Sepsis | |
| Fungal Sepsis | |
| Other Pathogens |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Sepsis Diagnosis Market Research FAQs
How big is the Global Sepsis Diagnostics Market?
The Global Sepsis Diagnostics Market size is expected to reach USD 0.74 billion in 2024 and grow at a CAGR of 6.58% to reach USD 1.02 billion by 2029.
What is the current Global Sepsis Diagnostics Market size?
In 2024, the Global Sepsis Diagnostics Market size is expected to reach USD 0.74 billion.
Who are the key players in Global Sepsis Diagnostics Market?
Abbott, Diasorin, Becton, Dickinson, and Company, bioMérieux SA and F. Hoffmann-LA Roche Ltd are the major companies operating in the Global Sepsis Diagnostics Market.
Which is the fastest growing region in Global Sepsis Diagnostics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Sepsis Diagnostics Market?
In 2024, the North America accounts for the largest market share in Global Sepsis Diagnostics Market.
What years does this Global Sepsis Diagnostics Market cover, and what was the market size in 2023?
In 2023, the Global Sepsis Diagnostics Market size was estimated at USD 694.39 million. The report covers the Global Sepsis Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Sepsis Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Sepsis Diagnostics Industry Report
The global sepsis market is segmented by technology, product, diagnostic method, pathogen, and geography. This comprehensive market analysis provides insights into the market size and forecasts in terms of value for these segments. The market report highlights key trends in molecular diagnostics, microbiology, immunoassay, and other technologies. The market research covers various products, including instruments, assays and reagents, and other products.
The diagnostic methods are categorized into conventional diagnostics and automated diagnostics, with a focus on bacterial sepsis, fungal sepsis, and other pathogens. The market overview includes a detailed examination of the market growth and market segmentation across North America, Europe, Asia-Pacific, Middle-East and Africa, and South America.
Industry reports indicate a robust market forecast outlook, with significant industry analysis and industry trends shaping the future of sepsis diagnostics. The market data and industry statistics provide a clear picture of the market value and market leaders. The market review and market predictions offer valuable insights for research companies, market leaders, and other stakeholders.
The report example and report PDF are available for a deeper dive into the market outlook and industry sales. The industry information and industry research included in the report underscore the importance of staying updated with the latest market trends and market growth. The industry size and growth rate further highlight the potential opportunities within the sepsis diagnostics market.
